loading page

Hesperidin Mitigates Bleomycin-Induced Testicular and Spermatological Damage in Rats
  • +2
  • İdris AYHAN,
  • Nese BASAK TURKMEN,
  • Saadet ALAN,
  • Muhterem AYDIN,
  • Osman Ciftci
İdris AYHAN
Pamukkale Universitesi

Corresponding Author:drssayhan@gmail.com

Author Profile
Nese BASAK TURKMEN
Inonu Universitesi
Author Profile
Saadet ALAN
Ankara Dr Abdurrahman Yurtaslan Onkoloji Egitim ve Arastirma Hastanesi
Author Profile
Muhterem AYDIN
Firat Universitesi
Author Profile
Osman Ciftci
Pamukkale Universitesi
Author Profile

Abstract

Bleomycin (BLM), a chemotherapeutic agent commonly used in cancer treatment, is associated with oxidative stress and testicular toxicity, leading to impaired reproductive health. Hesperidin (HES), a citrus-derived flavonoid with strong antioxidant properties, has the potential to counteract these adverse effects. This study aimed to evaluate the protective effects of HES against the reproductive toxicity induced by BLM, focusing on oxidative stress, sperm characteristics, and histological changes in the male reproductive system. Thirty-two rats were divided into four groups: Control, BLM, HES, and BLM+HES. BLM was administered intraperitoneally at 10 mg/kg twice a week, while HES was given orally at 50 mg/kg/day for 30 days. The findings revealed that BLM induced significant oxidative stress by promoting lipid peroxidation and impairing antioxidant defense mechanisms in the testis. Additionally, BLM treatment caused a marked decline in sperm motility, an increase in abnormal sperm rates, and severe histopathological damage in testicular tissue. However, co-administration of HES significantly mitigated these adverse effects by improving oxidative balance, restoring sperm quality, and reducing histopathological injuries. In conclusion, HES demonstrated potential in alleviating BLM-induced reproductive toxicity, suggesting its therapeutic role in protecting against chemotherapy-induced male infertility.
23 Jan 2025Submitted to Basic & Clinical Pharmacology & Toxicology
24 Jan 2025Submission Checks Completed
24 Jan 2025Assigned to Editor
24 Jan 2025Review(s) Completed, Editorial Evaluation Pending
02 Feb 2025Reviewer(s) Assigned